在癌症治疗中,KRAS抑制剂的新兴景观
Jakob M Riedl1, Hiroyuki Matsubara2, Reid McNeil2
1Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Cancer cell
|January 30, 2026
概括
在癌症中,RAS通路突变很常见. 虽然KRAS G12C抑制剂显示出前景,但耐药性限制了有效性. 下一代抑制剂旨在克服耐药性,并为更多患者提供更广泛的治疗效益.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 在约20%的癌症中,RAS通路的改变 (KRAS,NRAS,HRAS) 是普遍存在的.
- 突变选择性KRAS G12C抑制剂代表了向瘤性RAS的突破.
- 对第一代KRAS G12C抑制剂的耐药性需要开发新的治疗策略.
研究的目的:
- 审查各种癌症类型中KRAS G12C抑制剂的临床证据.
- 确定并讨论获得抗克拉斯G12C抑制剂耐药性的关键机制.
- 探索下一代 (K) RAS 抑制剂的前景,包括它们的机制,选择性和临床潜力.
主要方法:
- 对KRAS抑制剂的临床试验和临床前研究的文献综述.
- 在临床和实验环境中报告的耐药机制的分析.
- 基于目标覆盖范围和作用机制的新 (K) RAS 抑制剂类别的比较评估.
主要成果:
- 第一代KRAS G12C抑制剂证明了概念验证,但面临着重大抵抗挑战.
- 多种抗性机制,包括二次RAS突变和途径再激活,限制了持久的反应.
- 下一代抑制剂表现出多样化的机制和更广泛的目标配置文件,在临床前和早期临床研究中显示出前景.
结论:
- 克服耐药性对于最大化RAS向治疗的益处至关重要.
- 新型 (K) RAS 抑制剂有潜力绕过耐药性并为更广泛的患者群体扩大治疗选择.
- 需要进一步的临床研究来确定新兴的RAS向疗法的疗效和安全性.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
601
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
601
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Emerging Adulthood
683
Jeffrey Arnett's concept of emerging adulthood offers a framework to understand the unique developmental stage between adolescence and full-fledged adulthood, generally from ages 18 to 25. This period is marked by extensive exploration and shifts in identity, relationships, and career choices, a process known in psychology as role experimentation. Emerging adulthood reflects the evolving cultural expectations surrounding adulthood and the dynamic process of personal transformation during...
683
Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Introduction Cardiac Emergencies
363
Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
363
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
532
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
532


